The findings of this study suggest that a large percentage of metastatic cancer patients receiving myelosuppressive chemotherapy who are candidates for prophylactic G-CSF, per NCCN guidelines, do not receive it. The gene discussed is CSF3; the disease is metastatic malignant neoplasm.